25 Einträge gefunden

1. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

   1. Ludwig, Heinz
   2. Terpos, Evangelos
   3. van de Donk, Niels
   4. Mateos, Maria-Victoria
   5. Moreau, Philippe
   6. Dimopoulos, Melitios-Athanasios
   7. Delforge, Michel

   2023 - Forschungsinformationssystem des UKE
2. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

   1. Ludwig, Heinz
   2. Sonneveld, Pieter
   3. Facon, Thierry
   4. San-Miguel, Jesus
   5. Avet-Loiseau, Hervé
   6. Mohty, Mohamad
   7. Mateos, Maria-Victoria

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

   1. Moreau, Philippe
   2. Kumar, Shaji K
   3. San Miguel, Jesús
   4. Davies, Faith
   5. Zamagni, Elena
   6. Bahlis, Nizar
   7. Ludwig, Heinz

   2021 - Forschungsinformationssystem des UKE
4. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

   1. Ludwig, Heinz
   2. Boccadoro, Mario
   3. Moreau, Philippe
   4. San-Miguel, Jesus
   5. Cavo, Michele
   6. Pawlyn, Charlotte
   7. Zweegman, Sonja

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

   1. Ludwig, Heinz
   2. Pönisch, Wolfram
   3. Knop, Stefan
   4. Egle, Alexander
   5. Hinke, Axel
   6. Schreder, Martin
   7. Lechner, Daniel

   2020 - Forschungsinformationssystem des UKE
6. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

   1. Weisel, Katja
   2. Ludwig, Heinz
   3. Rieth, Achim
   4. Lebioda, Andrea
   5. Goldschmidt, Hartmut

   2020 - Forschungsinformationssystem des UKE
7. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

   1. Weisel, Katja
   2. Majer, Istvan
   3. DeCosta, Lucy
   4. Oriol, Albert
   5. Goldschmidt, Hartmut
   6. Ludwig, Heinz
   7. Campioni, Marco

   2020 - Forschungsinformationssystem des UKE
8. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

   1. Ludwig, Heinz
   2. Poenisch, Wolfram
   3. Knop, Stefan
   4. Egle, Alexander
   5. Schreder, Martin
   6. Lechner, Daniel
   7. Hajek, Roman

   2019 - Forschungsinformationssystem des UKE
9. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" ( 72 h): findings from the MONITOR-GCSF study

   1. Ludwig, Heinz
   2. Gascón, Pere
   3. Bokemeyer, Carsten
   4. Aapro, Matti
   5. Boccadoro, Mario
   6. Denhaerynck, Kris
   7. Krendyukov, Andriy

   2019 - Forschungsinformationssystem des UKE
10. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study

    1. Ludwig, Heinz
    2. Bokemeyer, Carsten
    3. Aapro, Matti
    4. Boccadoro, Mario
    5. Gascón, Pere
    6. Denhaerynck, Kris
    7. Krendyukov, Andriy

    2019 - Forschungsinformationssystem des UKE
11. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

    1. Bokemeyer, Carsten
    2. Gascón, Pere
    3. Aapro, Matti
    4. Ludwig, Heinz
    5. Boccadoro, Mario
    6. Denhaerynck, Kris
    7. Gorray, Michael

    2017 - Forschungsinformationssystem des UKE
12. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)

    1. Aapro, Matti
    2. Bokemeyer, Carsten
    3. Ludwig, Heinz
    4. Gascón, Pere
    5. Boccadoro, Mario
    6. Denhaerynck, Kris
    7. Gorray, Michael

    2016 - Forschungsinformationssystem des UKE
13. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

    1. Gascón, Pere
    2. Aapro, Matti
    3. Ludwig, Heinz
    4. Bokemeyer, Carsten
    5. Boccadoro, Mario
    6. Turner, Matthew
    7. Denhaerynck, Kris

    2016 - Forschungsinformationssystem des UKE
14. Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

    1. Gascón, Pere
    2. Aapro, Matti
    3. Ludwig, Heinz
    4. Bokemeyer, Carsten
    5. Boccadoro, Mario
    6. Turner, Matthew
    7. Denhaerynck, Kris

    2015 - Forschungsinformationssystem des UKE
15. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia

    1. Ludwig, Heinz
    2. Aapro, M
    3. Bokemeyer, C
    4. Glaspy, J
    5. Hedenus, M
    6. Littlewood, T J
    7. Osterborg, A

    2014 - Forschungsinformationssystem des UKE
16. Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study

    1. Abraham, Ivo
    2. MacDonald, Karen
    3. Tharmarajah, Soba
    4. Bokemeyer, Carsten
    5. Ludwig, Heinz
    6. Soubeyran, Pierre
    7. Battistel, Vittorio

    2013 - Forschungsinformationssystem des UKE
17. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.

    1. Canon, Jean-Luc
    2. Vansteenkiste, Johan
    3. Hedenus, Michael
    4. Gascon, Pere
    5. Bokemeyer, Carsten
    6. Ludwig, Heinz
    7. Vermorken, Jan

    2012 - Forschungsinformationssystem des UKE
18. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

    1. Palumbo, Antonio
    2. Bringhen, Sara
    3. Ludwig, Heinz
    4. Dimopoulos, Meletios A
    5. Bladé, Joan
    6. Mateos, Maria V
    7. Rosiñol, Laura

    2011 - Forschungsinformationssystem des UKE
19. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

    1. Cavo, Michele
    2. Rajkumar, S Vincent
    3. Palumbo, Antonio
    4. Moreau, Philippe
    5. Orlowski, Robert
    6. Bladé, Joan
    7. Sezer, Orhan

    2011 - Forschungsinformationssystem des UKE
20. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.

    1. Dimopoulos, Meletios A
    2. Terpos, Evangelos
    3. Chanan-Khan, Asher
    4. Leung, Nelson
    5. Ludwig, Heinz
    6. Jagannath, Sundar
    7. Niesvizky, Ruben

    2010 - Forschungsinformationssystem des UKE